Results from the EXPEDITE study of Remodulin® induction prior to Orenitram® therapy to be presented at ATS
Baseline patient data from the TETON studies of Tyvaso® Inhalation Solution in. | April 18, 2023
/PRNewswire/ United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today.
United Therapeutics submits new drug application to FDA to treat pulmonary arterial hypertension wraltechwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wraltechwire.com Daily Mail and Mail on Sunday newspapers.
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.